視網膜生技藥品市場規模、佔有率、成長分析，按藥物類別、按適應症、按分銷管道、按地區 - 行業預測，2025 年至 2032 年

預計 2023 年全球視網膜生技藥品市場規模將達到 229 億美元，並從 2024 年的 246.4 億美元成長到 2032 年的 442.7 億美元，預測期內（2025-2032 年）的複合年成長率為 7.6%。

視網膜疾病，尤其老齡化黃斑部病變(AMD)、糖尿病視網膜病變和視網膜靜脈阻塞的盛行率不斷上升，是人口老化面臨的迫切問題。生物技術的進步正在刺激對創新治療方法的需求，特別是在視網膜生技藥品領域，基因和細胞療法越來越受歡迎。抗盲基金會和美國黃斑部病變基金會等著名組織正在提高公眾意識並支持重要的研究舉措。受醫療基礎設施改善和糖尿病盛行率上升的推動，新興市場，尤其是中國、巴西和印度，將經歷顯著成長。總體而言，由於治療的進步、認知的提高以及全球對抗這些疾病的努力，視網膜生技藥品市場預計將擴大。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 案例研究
• 技術進步
• 貿易分析
• 客戶和購買標準分析

視網膜生技藥品市場規模（依藥物類別）

• 市場概況
• VEGF-A 拮抗劑
• TNF-α 抑制劑

視網膜生技藥品市場規模（依適應症分類）

• 市場概況
• 黃斑部病變
• 糖尿病黃斑部水腫
• 糖尿病視網膜病變
• 葡萄膜炎
• 其他

視網膜生技藥品市場規模（依分銷管道分類）

• 市場概況
• 機構投資人銷售
• 零售藥局
• 通訊藥房
• 零售

視網膜生技藥品市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• F. Hoffmann-La Roche Ltd（Switzerland）
• Regeneron Pharmaceuticals Inc.（USA）
• AbbVie Inc.（USA）
• Novartis AG（Switzerland）
• Bayer AG（Germany）
• Amgen Inc.（USA）
• Johnson & Johnson（USA）
• Biogen Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Bristol-Myers Squibb Company（USA）
• Sanofi Genzyme（France）
• Santen Pharmaceutical Co., Ltd.（Japan）
• Bausch & Lomb Incorporated（USA）
• Adverum Biotechnologies, Inc.（USA）
• MeiraGTx Holdings plc（UK）
• Oxurion NV（Belgium）
• Kodiak Sciences Inc.（USA）
• Clearside Biomedical, Inc.（USA）
• Neurotech Pharmaceuticals, Inc.（USA）
• Opthea Limited（Australia）

結論和建議

Global Retinal Biologics Market size was valued at USD 22.9 billion in 2023 and is poised to grow from USD 24.64 billion in 2024 to USD 44.27 billion by 2032, growing at a CAGR of 7.6% during the forecast period (2025-2032).

The increasing prevalence of retinal diseases, notably age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion, is a pressing concern driven by aging populations. Advances in biotechnology have catalyzed demand for innovative treatment options, particularly in retinal biologics, where gene therapy and cell-based therapies are gaining traction. Notable organizations, including the Foundation Fighting Blindness and the American Macular Degeneration Foundation, are enhancing public awareness and supporting critical research initiatives. Emerging markets, especially in countries like China, Brazil, and India, are poised for significant growth, fueled by improved healthcare infrastructure and rising diabetes rates. Overall, the retinal biologics market is primed for expansion, driven by advancements in treatment, increasing awareness, and a concerted global effort to address these conditions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Retinal Biologics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Retinal Biologics Market Segmental Analysis

Global Retinal Biologics Market is segmented by Drug Class, Indication, Distribution Channel and region. Based on Drug Class, the market is segmented into VEGF-A Antagonists and TNF-a Inhibitors. Based on Indication, the market is segmented into Macular Degeneration, Diabetic Macular Edema, Diabetic Retinopathy, Uveitis and Others. Based on Distribution Channel, the market is segmented into Institutional Sales, Retail Pharmacies, Mail Order Pharmacies and Retail Sales. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Retinal Biologics Market

One of the primary drivers of the Global Retinal Biologics market is the alarming rise in vision-related issues, particularly in the United States. According to data from the Centers for Disease Control and Prevention, millions are diagnosed with diabetic retinopathy, with many at risk of developing further complications that could severely affect their eyesight. The increasing incidence of this condition is expected to boost the demand for effective treatments, thereby propelling significant growth in the market. As a result, the escalating need for retinal biologics is anticipated to create a robust pathway for advancements and investment in this sector.

Restraints in the Global Retinal Biologics Market

One of the significant restraints in the Global Retinal Biologics market is the high cost associated with these therapies. These biologic drugs can be prohibitively expensive, limiting access for individuals in developing countries who struggle to afford them. Additionally, the complexity involved in the manufacturing and commercialization of retinal biologics, coupled with stringent regulatory requirements, poses further challenges. This combination of factors not only restricts the market potential but also creates barriers for patients needing these crucial treatments, ultimately hindering overall market growth and accessibility to life-changing therapies for those in need around the world.

Market Trends of the Global Retinal Biologics Market

The Global Retinal Biologics market is witnessing a significant trend towards genetic treatment approaches, driven by recent advancements in gene therapy research for retinal diseases, particularly inherited retinal dystrophies. These innovative therapies are transforming the landscape of retinal biologic drugs, offering targeted solutions that address the root causes of these conditions rather than just alleviating symptoms. As a result, the market is expected to experience robust growth, fueled by increasing investments in R&D, promising clinical trial outcomes, and a rising awareness of genetic therapies among patients and healthcare professionals. This shift underscores a broader movement towards personalized medicine in ophthalmology.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement
• Trade Analysis
• Customer & Buying Criteria Analysis

Global Retinal Biologics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• VEGF-A Antagonists
• TNF-a Inhibitors

Global Retinal Biologics Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Macular Degeneration
• Diabetic Macular Edema
• Diabetic Retinopathy
• Uveitis
• Others

Global Retinal Biologics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Institutional Sales
• Retail Pharmacies
• Mail Order Pharmacies
• Retail Sales

Global Retinal Biologics Market Size & CAGR (2025-2032)

• North America (Drug Class, Indication, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Indication, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Indication, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Indication, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Indication, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi Genzyme (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch & Lomb Incorporated (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adverum Biotechnologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MeiraGTx Holdings plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxurion NV (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clearside Biomedical, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurotech Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Opthea Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations